Compare DJCO & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DJCO | ZVRA |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 571.5M | 499.4M |
| IPO Year | N/A | 2015 |
| Metric | DJCO | ZVRA |
|---|---|---|
| Price | $577.60 | $8.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 71.0K | ★ 873.1K |
| Earning Date | 02-17-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.52 | N/A |
| EPS | ★ 81.41 | 0.54 |
| Revenue | ★ $87,700,000.00 | $84,388,000.00 |
| Revenue This Year | N/A | $333.25 |
| Revenue Next Year | N/A | $43.70 |
| P/E Ratio | ★ $7.15 | $16.06 |
| Revenue Growth | 25.41 | ★ 244.60 |
| 52 Week Low | $348.63 | $6.19 |
| 52 Week High | $584.70 | $13.16 |
| Indicator | DJCO | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 70.76 | 49.16 |
| Support Level | $481.64 | $8.21 |
| Resistance Level | $544.42 | $8.70 |
| Average True Range (ATR) | 26.69 | 0.36 |
| MACD | 3.38 | 0.03 |
| Stochastic Oscillator | 98.09 | 56.93 |
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.